How to Get GLP-1 Patients as a Psychiatrist in North Carolina

You’re a psychiatrist. You already have a full panel, maybe a waitlist. You’re comfortable with your psychiatric meds, your therapy skills, your billing systems. So why would you venture into weight-loss prescribing?

Here’s why: Nearly 20 million Americans are now on GLP-1 medications — drugs like Ozempic, Wegovy, and Mounjaro — and that number is growing by the week. Demand has exploded roughly 600% in six years. But here’s the opportunity most psychiatrists are missing: you’re uniquely positioned to serve this market better than anyone else.

Think about your current patients. How many are on antipsychotics that caused 40-pound weight gain? How many struggle with binge eating tied to their depression or anxiety? How many have asked you about these ‘miracle’ weight-loss drugs they see on social media?

Now think about the market beyond your current practice. Millions of patients can’t find providers to prescribe GLP-1s. Primary care docs are overwhelmed. Endocrinologists have six-month waits. And those direct-to-consumer telehealth companies? They’re converting patients by the thousands — but often without the behavioral health expertise that makes weight loss actually stick.

This is your lane. You understand behavior change. You manage chronic treatments. You’re comfortable with patient psychology, side effects, and the long game. And unlike most providers jumping into this space, you can actually address the mental health piece that everyone else ignores.

Why Psychiatrists Are Already Winning at GLP-1 Care

A late-2023 survey across major psychiatric departments found that nearly half of psychiatrists were already prescribing or recommending Ozempic or similar drugs. Not for vanity. For real clinical need — medication-induced weight gain, metabolic syndrome from antipsychotics, co-morbid obesity complicating psychiatric treatment.

Here’s what makes psychiatric providers different in the GLP-1 space:

You see the whole patient. When a patient on olanzapine gains 60 pounds and develops prediabetes, you can’t just ignore it and focus on their schizophrenia. Weight gain affects medication compliance, self-esteem, cardiovascular risk — all of which impact psychiatric outcomes. Adding GLP-1 treatment isn’t scope creep; it’s comprehensive care.

You understand behavior change. Weight loss isn’t just about injecting semaglutide weekly. It’s about changing eating patterns, managing stress without food, dealing with body image issues, staying motivated through plateaus. You do this work every day with psychiatric patients. Translating it to weight management is natural.

You can spot and manage psychiatric side effects. In 2023, there were concerns about GLP-1s potentially increasing suicidal ideation. The FDA investigated and found no causal link — they even directed removal of suicide warnings from labels in early 2026. But guess who’s best positioned to monitor for mood changes, anxiety, or disordered eating on these meds? A psychiatrist. That’s a competitive advantage.

You have existing patient relationships. Starting GLP-1 treatment with your current patients is the lowest-friction path to building expertise and volume. No patient acquisition cost. No marketing. Just clinical conversations with people who already trust you.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

The Business Case: Real Numbers on Patient Demand and Economics

Let’s talk money, because this isn’t charity work.

Patient volume is there. By 2025, an estimated 6% of Americans (about 20 million people) were actively taking GLP-1 drugs. With roughly 75% of Americans overweight or obese, the addressable market is massive — and most patients can’t access these medications through traditional channels because providers are maxed out or insurance won’t cover it.

Patients are willing to pay. The majority of GLP-1 weight-loss patients are self-pay because insurance coverage is limited. As of mid-2024, only 13 state Medicaid programs covered GLP-1s for weight loss (though that’s expanding). Most private plans exclude obesity medications. This means patients know they’re paying out-of-pocket and they’re doing it anyway — often $200-400/month for compounded semaglutide, or $1,300+ for brand-name Wegovy without insurance.

Your revenue model can be straightforward:

• Initial consultation: $200-350 for a comprehensive 45-60 minute telehealth eval (medical history, labs review, weight/metabolic assessment, goal-setting, medication education)
• Follow-up visits: $100-150 for 15-20 minute monthly check-ins during titration phase (first 3-6 months), then every 2-3 months for stable patients
• Subscription model alternative: Some providers charge $99-199/month for ongoing care, medication management, and access to support resources

If you see 20 GLP-1 patients at $150/month average (mix of new and follow-up visits), that’s $3,000/month in additional revenue — $36,000/year. Scale to 50 patients and you’re adding $90,000 annually. And these visits are efficient: standardized workflows, brief telehealth follow-ups, minimal documentation compared to complex psychiatric cases.

How to Actually Get GLP-1 Patients: Three Paths That Work

Path 1: Start with Your Existing Panel (Fastest, Zero Marketing Cost)

This is the no-brainer move. Review your current caseload and identify patients who:

• Gained significant weight on psychiatric medications (antipsychotics, mood stabilizers, mirtazapine, etc.)
• Have BMI ≥30, or ≥27 with weight-related comorbidities (hypertension, prediabetes, sleep apnea)
• Have expressed frustration about weight or asked about GLP-1s
• Struggle with binge eating or emotional eating alongside their psychiatric diagnosis

Bring it up proactively in medication reviews. ‘I know the Zyprexa has been really helpful for your mood stability, but I also know you’ve gained 40 pounds since we started it. I’ve been offering weight-loss medication to some patients — GLP-1s like semaglutide — and seeing good results. Would you be interested in talking about that?’

Many patients will say yes immediately. Some will be relieved you brought it up. This converts existing patients into a new service line with zero acquisition cost.

Path 2: Join a Telehealth Platform That Delivers Qualified Patients

If you want volume fast without building marketing infrastructure, join a platform that already does patient acquisition. This is the smart economic play for most providers.

Here’s the reality of DIY patient acquisition for GLP-1 care:

• SEO takes 6-12 months of consistent content creation, backlink building, and technical optimization before you see meaningful patient flow. Most solo providers don’t have the expertise or patience.
• Google Ads for weight loss keywords cost $15-40+ per click. Most clicks don’t convert to booked patients. A realistic cost per booked patient through PPC is $200-400+, sometimes more.
• Directory listings (Psychology Today, Zocdoc) charge monthly subscription fees AND often per-booking fees. You’re competing with hundreds of other providers on the same page. Total monthly cost easily runs $500-1,500 even before patient volume justifies it.

When you factor in ALL costs — agency/consultant fees if you hire help, ad spend for testing and optimization, staff time to handle and qualify leads, no-show rates from cold leads — acquiring a psychiatric patient through DIY marketing typically costs $200-500+ per patient when you’re starting out.

Platforms like Klarity offer a smarter model:

• No upfront marketing spend or monthly subscription fees
• Pay a standard listing fee per new patient appointment — only when you actually see someone
• Patients are pre-qualified and matched to your specialty and availability
• Built-in telehealth infrastructure (no separate platform costs)
• Both insurance and cash-pay patient flow
• You control your schedule — decline appointments if you’re full

Instead of gambling $3,000-5,000/month on marketing with uncertain results, you pay only when a qualified patient books with you. That’s guaranteed ROI. For providers starting out or scaling, this removes all the risk.

Path 3: Strategic Marketing If You Want to Build Your Own Brand

If you’re committed to building a standalone GLP-1 practice, you need to market intelligently:

SEO (long-term investment):

• Create content on your website about GLP-1s and mental health: ‘Managing Weight Gain from Psychiatric Medications,’ ‘Why Psychiatrists Make the Best Weight-Loss Doctors,’ etc.
• Target local keywords: ‘GLP-1 doctor [your city],’ ‘psychiatric weight management [state]’
• This takes months to pay off, but once it does, you own the traffic

Social media (educational + testimonials):

• Share patient success stories (with permission): ‘Patient lost 45 lbs on semaglutide while staying stable on lithium’
• Post educational content: ‘Did you know antipsychotics can cause 15-30 lb weight gain? Here’s what we can do about it’
• Use platforms like Instagram, TikTok (short-form video is huge for health content), LinkedIn for professional networking

Referral partnerships:

• Let primary care doctors, endocrinologists, and therapists in your area know you’re prescribing GLP-1s
• Emphasize that you’ll co-manage with them and send updates
• Many PCPs are relieved to refer this work out — they don’t have time for monthly weight-loss follow-ups

Local advertising:

• Google Ads targeted to your zip codes (expensive but immediate)
• Facebook/Instagram ads to people interested in weight loss + mental health
• Emphasize your psychiatric expertise: ‘Psychiatrist-led weight loss program addressing the emotional side of eating’

The key differentiator in your marketing: you’re not just another weight-loss clinic. You’re a psychiatrist who treats the whole person — the mental health drivers of weight gain, the psychological barriers to behavior change, the mood effects of rapid weight loss. That positioning attracts higher-quality patients who want comprehensive care, not just quick meds.

What Makes Psychiatric Providers Uniquely Valuable in the GLP-1 Market

Integrated care that actually works. Weight and mental health are intertwined. Depression can lead to emotional eating. Anxiety can drive stress eating. Binge eating disorder is literally a psychiatric diagnosis. Yet most weight-loss clinics ignore this entirely — they hand out medication and maybe a pamphlet about diet.

You can do better. You can screen for eating disorders. You can address anxiety that might worsen when patients change their eating patterns. You can help patients develop healthier coping mechanisms than food. This integrated approach leads to better outcomes — and better outcomes lead to word-of-mouth referrals, higher patient retention, and premium pricing.

You’re comfortable with long-term medication management. GLP-1 therapy isn’t a six-week antibiotic course. It’s a chronic treatment, often lasting years. Patients need ongoing monitoring, dose adjustments, side effect management, and motivation. This is literally what psychiatrists do with antidepressants, antipsychotics, and mood stabilizers. You know how to manage chronic treatments and keep patients engaged.

You can navigate complex cases. What happens when a patient on GLP-1s develops depression (whether related or coincidental)? What if they have a history of anorexia and you’re concerned about restriction? What about the patient with schizophrenia on clozapine who desperately needs to lose weight but also needs his antipsychotic? Most weight-loss providers would refer out or decline. You can manage this.

Setting Realistic Expectations: What to Tell Patients (and Yourself)

GLP-1s are powerful, but they’re not magic. Here’s what honest, ethical psychiatric providers should communicate:

Expected outcomes:

• Patients typically lose 10-20% of body weight over 12-18 months on therapeutic doses
• Not everyone responds — about 10-15% of patients are ‘non-responders’ who lose minimal weight
• Weight loss is faster initially (months 1-6), then slows
• Combining medication with lifestyle changes (nutrition, exercise, behavioral support) yields best results

Common side effects:

• GI issues (nausea, vomiting, diarrhea, constipation) are very common, especially during dose escalation
• Usually improve after a few weeks, but some patients can’t tolerate the meds
• Rare serious risks: pancreatitis, gallbladder disease, thyroid tumors (mainly in animal studies)

Cost transparency:

• Most patients pay out-of-pocket: $200-400/month for compounded semaglutide, $1,300+/month for brand Wegovy
• Some insurance covers it for diabetes, rarely for obesity alone
• Be upfront about total monthly cost: medication + your visit fees

This is not a quick fix:

• Patients need to commit to regular follow-ups, lifestyle changes, and potentially staying on medication long-term
• Many regain weight if they stop medication abruptly
• Position GLP-1 as a tool to improve health (reduce diabetes risk, improve blood pressure, decrease joint pain) — not purely cosmetic

This honest approach attracts motivated, realistic patients and avoids dissatisfaction. It also protects you legally — informed consent is critical.

The Bottom Line: Why Now Is the Time

The GLP-1 market is booming, but it’s not oversaturated — especially for providers with psychiatric expertise. Surveys show a shortage of obesity medicine specialists relative to the millions of interested patients. In most regions, you’ll face little competition, especially for telehealth where you can reach underserved areas.

Starting this service line now gives you first-mover advantage in your local market. You build expertise, referral relationships, and online visibility before everyone else catches on. And the demand isn’t going away — obesity rates continue rising, and GLP-1 drugs are becoming more affordable (generics, biosimilars in development).

For psychiatrists specifically, this is about providing better care to the patients you already see — and meeting massive unmet demand in the broader population. You don’t have to abandon psychiatric practice. Many providers do a hybrid model: 60-70% psychiatry, 30-40% weight management. Others fully transition. Either way, adding GLP-1 prescribing diversifies your revenue, attracts new patients, and positions you as a comprehensive provider who treats the whole person.

The opportunity is real. The demand is there. The question is whether you’ll act on it.

Frequently Asked Questions

Do I need special training or certification to prescribe GLP-1s for weight loss?

No formal certification is required. As a physician, you can legally prescribe GLP-1s off-label for obesity (semaglutide for obesity is FDA-approved as Wegovy, though many use Ozempic off-label; tirzepatide is approved as Mounjaro for diabetes and Zepbound for obesity). That said, taking CME courses in obesity medicine or GLP-1 management is smart — it builds your confidence and clinical competence. Organizations like the Obesity Medicine Association offer online courses. Even a few hours of structured learning will give you protocols for dosing, managing side effects, and patient selection.

Can psychiatric NPs (PMHNPs) prescribe GLP-1s, or is this only for MDs/DOs?

It depends on your state. In states with full practice authority for NPs (like California after 2026, New York for experienced NPs, Illinois with FPA certification), PMHNPs can prescribe GLP-1s independently. In restrictive states (Texas, Pennsylvania, Florida for psych NPs), you’ll need a collaborative agreement with a physician. GLP-1s are not controlled substances, so the barriers are lower than for stimulants — but you still need to work within your state’s scope of practice rules.

How much time do GLP-1 follow-ups actually take?

Initial consults are longer — 45-60 minutes to cover medical history, labs, weight/metabolic assessment, medication education, goal-setting, and mental health screening. Follow-ups during the titration phase (first 3-6 months) are typically 15-20 minutes monthly: check weight progress, manage side effects, adjust dose, provide brief behavioral coaching. Once patients are stable on a maintenance dose, you can space visits to every 2-3 months. Many providers use standardized templates and questionnaires to streamline documentation, making these visits efficient.

What if a patient has psychiatric comorbidities — can I still prescribe GLP-1s?

Generally yes, but screen carefully. GLP-1s are safe for most patients with depression, anxiety, or stable psychiatric conditions. In fact, some early research suggests GLP-1s might have positive effects on mood in certain populations. However, use caution with:

• Active eating disorders (anorexia, bulimia) — rapid weight loss could worsen restriction or purging
• Severe, unstable psychiatric illness where adherence to medication and follow-up is questionable
• History of pancreatitis (relative contraindication for GLP-1s)

Always screen for eating disorders and document your risk assessment. For complex cases, consider co-managing with a psychiatrist or therapist.

Do I need malpractice insurance that covers weight-loss prescribing?

Check with your current malpractice carrier. Most physician policies cover prescribing medications within your scope of practice, and GLP-1 prescribing falls under general medical practice. However, if you’re adding a significant weight-management service line, inform your insurer to ensure coverage. Some carriers might require an addendum or slightly higher premium if obesity medicine becomes a large part of your practice. NPs should also verify their policy covers services outside their core specialty (though prescribing for metabolic/weight issues is generally considered within PMHNP scope if you’re managing psychiatric medication side effects).

Is telehealth GLP-1 prescribing legal in my state?

Yes, in all states, as long as you’re licensed in the patient’s state and follow standard telemedicine rules. GLP-1s are not controlled substances, so the federal Ryan Haight Act (requiring in-person visits for controlled substance prescribing) doesn’t apply. Most states allow you to establish a patient relationship via synchronous video and prescribe non-controlled medications. Some states (like California) require patient consent for telehealth, and a few have specific telehealth practice standards, but none outright prohibit GLP-1 prescribing via telemedicine. Just ensure you conduct a proper evaluation (video visit is standard), document appropriately, and follow any state-specific telehealth requirements.

Top 5 Citations

1. Axios – ‘More than 2% of Americans used GLP-1 agonists for weight loss in 2024’ (May 27, 2025) – Reputable news source reporting on Fair Health claims data showing ~600% increase in GLP-1 weight-loss usage over six years. www.axios.com

2. ConfectioneryNews – ‘GLP-1 drugs like Ozempic are reshaping health, diet and the food industry’ (Oct 20, 2025) – Industry news citing expert estimates that 6% (20 million) Americans were on GLP-1 drugs by late 2025, with 75% of Americans overweight or obese. www.confectionerynews.com

3. Time Magazine – ‘The Heavy Cost of Using Weight-Loss Drugs to Get Skinny’ (Aug 22, 2025) – Major publication discussing insurance coverage gaps for GLP-1 obesity treatment, noting most insurances cover these medications for diabetes but not weight loss, leading to high out-of-pocket costs. time.com

4. Axios – ‘America’s doctors need more obesity medicine training’ (May 28, 2024) – News report highlighting that the relatively small number of obesity medicine specialists struggle to meet demand for GLP-1 agonists, with patients often waiting months for appointments, and noting that patients on these drugs should be regularly monitored. www.axios.com

5. PharmaNews Intelligence (via Schizophrenia Forum) – ‘Nearly half of psychiatrists prescribe or recommend Ozempic’ (Nov 6, 2023) – Survey-based industry report indicating significant psychiatric provider engagement with GLP-1 prescribing, particularly for medication-induced weight gain. forum.schizophrenia.com

Source:

• https://www.axios.com/2025/05/27/american-glp1-use-weight-loss-increasing#:~:text=More%20than%202,their%20original%20approved%20use
• https://www.confectionerynews.com/Article/2025/10/20/glp-1-drugs-like-ozempic-are-reshaping-health-diet-and-the-food-industry/#:~:text=GLP,real%20number%20according%20to%20Kim
• https://forum.schizophrenia.com/t/psychiatrists-recommend-ozempic/311318#:~:text=Drugs%20pharmanewsintel
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=equivalent%20to%20in,FDA%2C%20pharmacy%2C%20and%20board%20alerts
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,with%20chart%20review%2C%20plus%20meetings
• https://www.singleaimhealth.com/news/nurse-practitioner-collaborative-agreement-templates-50-state-guide#:~:text=In%20Pennsylvania%2C%20Certified%20Registered%20Nurse,the%20CRNP%20and%20the%20collaborating
• https://www.wheel.com/state-telehealth-regulations/florida#:~:text=Are%20There%20Online%20Prescription%20Restrictions,for%20Telehealth%20in%20Florida
• https://time.com/7311517/cost-weight-loss-drugs-skinny/#:~:text=most%20insurances%20cover%20the%20medication,A%20recent%20Annals%20of%20Internal
• https://www.axios.com/2024/11/05/states-slow-to-cover-glp-1s-for-weight-loss#:~:text=What%20they%20found%3A%20In%20all%2C,a%20primary%20concern%2C%20KFF%20found
• https://time.com/7311517/cost-weight-loss-drugs-skinny/#:~:text=But%20these%20medications%20were%20originally,diabetes%2C%20weight%20loss%20treatment%20is